4mg-30s (Silodosin 4mg 30s Container Label)
Silodosin Capsule
Product Images NDC 72205-009
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 72205-009). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
8mg-30s (Silodosin 8mg 30s Container Label)
Silodosin Capsules are a medication that come in packs of 30, each capsule containing 8mg of medication. The suggested dosage is one capsule per day taken orally with food, and the package insert should be consulted for complete instructions. This medication should be stored at room temperature between 15°C to 30°C (59°F to 86°F), with a controlled room temperature between 25°C (77°F). The manufacturer is MSN Laboratories in India, and the medication is distributed by Novadoz Pharmaceuticals. This medication requires a prescription.*
8mg-90s (Silodosin 8mg 90s Container Label)
Each capsule of Silodosin contains 8mg of medication and is to be taken once a day with a meal. It is distributed by Novadoz Pharmaceuticals LLC and comes in a pack of 90 capsules with NDC 72205-010-90. The packaging has a full prescribing information insert for reference. The capsules should be stored and dispensed at a controlled room temperature of 15°C to 30°C (59°F to 86°F) and kept away from light and moisture. This medication should be kept out of the reach of children. The issue date of the packaging is 01/2021 and the manufacturer is indicated as MSN Laboratories Private Limited in Telangana, India.*
Figure-01 (Silodosin Figure 01)
Fig-2 (Silodosin Figure 02)
This is a statistical measurement of the change in IPSS (International Prostate Symptom Score) total score from the baseline. The value of p is less than 0.0001 indicating statistical significance. The rest of the text appears to be a record of values or dates, but without context, it is not possible to provide specific information.*
Fig-3 (Silodosin Figure 03)
The text contains statistical information regarding the change in IPSS total score, with a significant p-value of less than 0.0001. No further contextual information is available.*
Fig-4 (Silodosin Figure 04)
The text provides statistical information related to the change from baseline in Qmax (maximum urinary flow) in a clinical trial. The data suggests that there was a significant (*p<0.05) increase in Qmax in the group receiving 8mg of a treatment (not specified due to limitations) compared to a placebo group. The timeline of the study is also provided, with Qmax measurements taken on days 1, 7, 14, 28, and 84 (or last observation carried forward).*
Fig-5 (Silodosin Figure 05)
Structure (Silodosin Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
